Sangamo issues $996k in stock, to pay earn-outs for gene therapy firm Ceregene
Sangamo BioSciences Inc. (protein medicines targeting DNA) has acquired Ceregene Inc., a private gene therapeutics developer. Sangamo is issuing 100k shares valued at $996k up front, representing less than 0.2% of its outstanding stock. Ceregene may also receive a certain amount of cash and cash equivalent minus certain liabilities and expenses.
- Medical Devices
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.